期刊文献+

巴戟天寡糖对抑郁症患者血浆IL-6和TNF-α的影响

Effects of morinda officinalis oligose on plasma IL-6 and TNF-α levels in patients with depression
收藏 分享 导出
摘要 目的:探讨巴戟天寡糖对抑郁症患者血浆白细胞介素-6(interleukin-6,IL-6)和肿瘤坏死因子-α(tumor necrosis factor,TNF-α)的影响及其与临床疗效的关系。方法:本研究入组符合国际疾病分类第10版(ICD-10)抑郁发作诊断标准的门诊患者32例,入组后单一巴戟天寡糖胶囊治疗,疗程8周,每2周访视1次,评估患者的抑郁症状变化及药物安全性。疗效标准为汉密尔顿抑郁量表(hamilton depression rating scale-17,HAMD-17)总分变化。入组前后各采血1次,采用酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)测定患者治疗前后血浆IL-6及TNF-α的浓度变化。对患者治疗前后血浆IL-6及TNF-α的浓度变化与疗效及安全性指标进行关联分析,探讨巴戟天寡糖胶囊抗抑郁作用可能的潜在药理学机制。结果:巴戟天寡糖胶囊抗抑郁治疗后,入组患者在第2,4,6和8周末HAMD-17评分均显著降低(均P <0. 01);治疗后血浆IL-6和TNF-α浓度均显著下降(均P <0. 01);对治疗有效组和无效组进行协方差分析。结果显示,治疗后有效组和无效组血浆IL-6及TNF-α浓度均无统计学差异(均P>0. 05)。结论:巴戟天寡糖胶囊可以改善抑郁症患者的抑郁症状,巴戟天寡糖可降低抑郁症患者血浆IL-6和TNF-α水平。 Objective:To investigate the effects of morinda officinalis oligose on plasma interleukin-6(IL-6)and tumor necrosis factor(TNF-α)levels in patients with depression.Methods:Thirty-two patients who had a diagnosis of major depression according to international classification of diseases-10(ICD-10)were included and treated with morinda officinalis oligoes for 8 weeks.Changes of depressive symptoms and side reactions were assessed biweekly.Hamilton depression rating scale-17(HAMD-17)were employed to the main efficacy criteria.The plasma levels of IL-6 and TNF-αbefore and after the treatment were measured by enzyme-linked immunosorbent assay(ELISA).By correlating the changes of plasma levels of IL-6 and TNF-αwith efficacy and safety indicators,we investigated the potential pharmacological mechanism of morinda officinalis oligoes.Results:HAMD-17 scores decreased significantly after 2,4,6 and 8 weeks of treatment(P<0.01).Compared with baseline,significant effectwas observed on plasma levels of IL-6 and TNF-αafter morinda officinalis oligose treatment(P<0.01).The covariance analysis revealed,no differences were observed in plasma levels of IL-6 and TNF-αbetween the patients with and without response to morinda officinalis oligoes(P>0.05).Conclusion:Morinda officinalis oligose can improve depressive symptoms and decrease IL-6 and TNF-αlevels.
作者 慕永刚 邓朔 张素贞 宫小云 李玲芝 郭丽华 施莹 宓为峰 张鸿燕 MU Yong-gang;DENG Shuo;ZHANG Su-zhen;GONG Xiao-yun;LI Ling-zhi;GUO Li-hua;SHI Ying;MI Wei-feng;ZHANG Hong-yan(The Third People's Hospital of Huzhou City,Huzhou 313000,China;Bejing Minkang Hospital,Beijing 102206,China;Peking University Sixth Hospital,Peking University Institute of Mental Health,Key Laboratory of Mental Health,Ministry of Health(Peking University),National Clinical Research Center for Mental Disorders(Peking University Sixth Hospital),Beijing 100083,China)
出处 《中国新药杂志》 CAS CSCD 北大核心 2019年第8期926-929,共4页 Chinese Journal of New Drugs
基金 国家“重大新药创制”科技重大专项资助项目(2014ZX9301307014) 国家“重点研发计划”资助项目(2016YFC1304404).
关键词 巴戟天寡糖 抑郁症 白细胞介素-6 肿瘤坏死因子-Α morinda officinalis oligose depressive disorders interleukin-6 tumor necrosis factor
作者简介 慕永刚,男,硕士,医师,主要从事精神疾病治疗和临床药理研究。联系电话:15669531627,E-mail:myg613@163.com;通讯作者:张鸿燕,女,硕士生导师,主任医师,主要从事精神科临床及新药研究。联系电话:(010)82801940,E-mail:sally_zhy@sina.com;通讯作者:宓为峰,女,博士,助理研究员,主要从事精神科临床及新药研究。联系电话:13811403389,E-mail:miwf2007@126.com。
  • 相关文献

参考文献10

二级参考文献56

共引文献177

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈